Home › Compare › TREAY vs ABBV
TREAY yields 1.93% · ABBV yields 3.06%● Live data
📍 TREAY pulled ahead of the other in Year 4
Combined, TREAY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TREAY + ABBV for your $10,000?
Terna Energy Societe Anonyme Commercial Technical Company operates in the renewable energy sources (RES), construction, trading of electric energy, and concessions sectors in Greece, Balkans, Eastern Europe, and North America. The company constructs, exploits, and installs renewable sources of wind and hydroelectric energy, photovoltaic parks. It also owns and operates wind parks, hydroelectric projects, pumped storage, hybrid stations, and photovoltaics, as well as PPP waste management projects, the production of biofuels, soil conditioners and other products. In addition, the company engages in the construction and operation of infrastructure and public sector projects, such as unified automatic collection system and municipal waste treatment facilities in Epirus region. As of December 31, 2021, the company had operational power of approximately 1,300 MW and installed capacity of 895.3 MW. Terna Energy Societe Anonyme Commercial Technical Company was founded in 1949 and is based in Athens, Greece.
Full TREAY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.